Fast Forward

Glialogix, National Multiple Sclerosis Society collaborate

Thursday, October 2, 2014

Glialogix, a San Francisco Bay Area-based emerging biopharma company, has entered into a sponsored research agreement with Fast Forward, a nonprofit organization established by the New York-based National Multiple Sclerosis (MS) Society to accelerate the development of treatments for MS. Fast Forward will provide funding for preclinical studies of GLX1112, a first-in-class neuroprotective therapy designed to slow the accumulation of disability in progressive MS.

[Read More]

MediciGlobal appoints Linda Capsey vice president

Thursday, August 21, 2014

MediciGlobal, a global provider of patient recruitment and retention for clinical trials with offices in Pennsylvania and London, has appointed Linda Capsey, Ph.D., vice president project management and innovation. Capsey will provide strategic and operational oversight for recruitment-retention program development, site training workshops for patient communications and informed consent, and work as a consultant to biopharmaceutical companies for patient recruitment-retention planning and feasibility.

[Read More]

Linegen, Fast Forward collaborate to develop gene and biomarker assays for MS

Friday, December 16, 2011

Lineagen and Fast Forward, a nonprofit subsidiary of the National Multiple Sclerosis Society, have formed an alliance to fund the clinical development and validation of a blood-based assay for multiple sclerosis (MS). The goal of the program is to develop a test that can aid clinicians in diagnosing MS, distinguishing it from other neurological disorders, and providing the prognostic information needed to help guide treatment decisions and response to therapies.

[Read More]